This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
in 2013 to 8.2% Overall spending by employers and employees on mental health services as a percentage of total spending rose from 6.8% in 2020, the report found. The use of the mental health services also increased, especially in outpatient settings.
Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.
It’s the second partnership between the two companies; an alliance that began in 2013 expired without Gilead licensing any molecules from the deal. Gilead Sciences is betting that a MacroGenics antibody drug for blood cancers can offer a safety edge over others that address the same target.
After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis. |
The company in 2022 claimed the research university breached its contracts relating to a joint trial the two ran in 2013 and wrongly secured patents for itself from the study. Patent and Trademark Office (PTO) to weigh in following a 2022 complaint. | Now, Merck is taking its complaints to the patent office.
2013 Most Influential Sales Recruitment Firms across America – MedCepts recruiting division ranks #2 of 6,000 Recruitment Firms in USA for 2013 for the Most Influential Sales Recruitment Firms. MedCepts Receives Top Recruiter Award as recognition of being in the top Most Influential Sales Recruitment firms across America.
In 2013 she threw in her lot with BioNTech. The basic mRNA technology was primarily developed by Katalin Karikó and Drew Weissman when both worked at the U of Pennsylvania, where higher-ups dismissed Karikó as deadwood unworthy of university support. And how did Pfizer reward this partnership?
AbbVie has also raised the price of Imbruvica by 82% since launching the drug in 2013. For a patient taking 3 tablets daily, the annual net price of Imbruvica increased from $72,587 in 2013 to $115,533 in 2017 (the last year for which AbbVie provided the Committee data). billion in 2013—the year it separated from Abbott—to $16.1
Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years
Moreover, localized lung cance r diagnoses rose to 28% in 2018 from 20% in 2013— the year that the U.S. The 5-year survival rate has increased by 6% for distant-stage lung cancer, 33% for a regional-stage disease, and 60% for localized disease.
One-quarter of all cancer patients chose not to fill a prescription due to cost, according to a 2013 study in The Oncologist. According to a study published in the American Journal of Medicine, more than 42 percent of the 9.5 million people diagnosed with cancer from 2000 to 2012 drained their life’s assets within two years.
The Defense Threat Reduction Agency, a division of the Department of Defense, provided more than $10 million of funding in 2013 and 2015 to Emory University, as research done by the nonprofit Knowledge Ecology International has revealed.
HCPs are also connecting more than ever: one study showed that HCP posts about healthcare increased from 10% in 2013 to 50% in 2019. According to Sermo, two-thirds of physicians spend at least an hour on social media, with an average daily use of two hours and twenty-two minutes. 33 Even now, nearly 70% of all HCPs are digital natives.
Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted. Richard has facilitated AbbVie securing a market capitalisation increase from $54 billion in 2013 to over $300 billion in 2024.
However, despite the momentum the bill has gained throughout the years, the Treat and Reduce Obesity Act (commonly known as TROA) has yet to come up for a committee or floor vote since it was first introduced in 2013. It needs to be passed NOW but even this won’t be enough.
Recent big pharma ABPI members While Novo Nordisk became a member of the APBI in 2013, other additions in recent years include Moderna, who gained membership in January 2023 , and Gilead, who joined the ABPI in January 2022. The post Novo Nordisk industry membership reinstated appeared first on European Pharmaceutical Review.
household income from 2009 to 2013 was $53,046, according to the United States Census Bureau, but many of the most recently approved anticancer treatments approved by the United States Food and Drug Administration (FDA) are priced well above $100,000 per year. ASH Clinical News takes it a step further.
Figure 2: Impact – The citation impact (measured by Category Normalized Citation Impact, or CNCI) of the papers published by each country/region, presented in both an Impact Profile and the trend for 2013-2022. Figure 3: Output – Trends in international output and open access output for 2013-2022 for each G20 member nation.
A Journal of the American Medical Association ( JAMA ) study investigated how five key factors were associated with healthcare increases from 1996 to 2013: Service price and intensity Population growth Population aging Disease prevalence or incidence Medical service utilization.
” Roughly 40% of all US cases of incident diabetes during 2013-2016 were directly attributable to obesity , a finding that further solidifies the major etiologic role for obesity in the current American diabetes epidemic. Fewer than 10 percent of American adults ate enough vegetables in 2013. Dr. Natalie A.
billion on R&D from 2013 to 2018. In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 Porter (D-Calif.) pointed out that the company spends nearly double that—$4.7
Construction at the Carrigtwohill facility built in 2013 is set to begin in 2023. AbbVie , an international R&D biopharmaceutical enterprise has celebrated its 20th anniversary by investing in extensive renovations at its manufacturing site in Cork, Ireland.
In episode 112, Nima Farzan, CEO of Kinnate, who was one of Pharmaceutical Executive’s Emerging Pharma Leaders in 2013, discusses how he’s successfully navigated his career path, from building a foundation in pharma to growing his expertise in biotech.
The report, Clinical Trials – The Importance of Diversity in Clinical Trials , examined data from clinical trials initiated between 1 January 2013 and 16 June 2022. Diversity within the pharmaceutical sector and clinical trials continues to be a problem, according to a recent report by data and analytics company GlobalData.
in 2013 to 19.3% The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.
He rose to the position of head of global product strategy at Roche in 2013, before taking the CEO role at Genentech in 2017 and then group head pharma in January 2019. There’s no word yet on where Anderson will continue his career, but a CEO role at a biotech company seems a likely destination.
An earlier case of contamination from 2013 of manufactured steroid injections containing methylprednisolone acetate was also mentioned in the paper. The authors stated that the presence of Aspergillus penicillioides in antimicrobial preoperative skin preparation drugs were attributed to inadequate storage conditions.
Since 2013, Barr has worked as Senior Vice President, Head of Research and Product Development of Alexion, AstraZeneca’s rare disease group. She will work across Cardiovascular, Renal & Metabolism and Respiratory & Immunology.
Chiesi’s involvement with Lamzede dates back to 2013, when it acquired the drug’s original developer Zymenex and used it as the foundation for a protein-based therapeutics division. At the moment, almost three quarters of the Italian drugmaker’s turnover is in Europe, with 15% from the US and 13% from the rest of the world.
More than 480 warning letters solely related to the failure to produce aseptic conditions because of deficient cleaning and disinfection systems for cleanrooms and their equipment, were issued by regulators between 2013 to 2018. Microbial resistance is one of the factors responsible for such failings.
The most recent guide was published by the WHO in 2013. The study, which was funded by the Wellcome Trust, also reveals the urgent need for global antibiotic guidelines to be updated, to reflect the rapidly evolving rates of AMR. The WHO has declared AMR as one of the top 10 global public health threats facing humanity.
A wide-ranging systematic review undertaken in 2013 identified a total of 771 individual factors influencing likelihood of non-adherence, clustering into socio-economic, healthcare team, system, condition, therapy, and patient-related factors.
Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
Angela spent a decade in pharma sales and marketing management roles with MSD and BMS, prior to staring the world’s second market access agency in 1998, which she sold to IMS Health in 2013. She is an SME in market access, rare disease and biosimilars.
The Novartis-MIT project culminated in a 2013 publication describing an end-to-end continuous process to produce aliskiren drug substance, and formulated drug product, at pilot scale. For pharmaceuticals, the motivating factors likely include the desire for greater quality control, along with expected improvements in safety and efficiency.
18% of study participants were Black/African American in 2013, but that contracted to 14% in 2020 and then plunged to just 9% in 2021. For Hispanics, participation in trials increased from 7% in 2012 to a high of just under 10% in 2017 but fell back to levels of around 8% to 9% in the past two years.
GSK licensed otilimab from German biotech MorphoSys in 2013 in a deal valued at up to €423 million, including around €23 million upfront. Daprodustat backed. There has been somewhat better news for GSK for another of its top pipeline prospects – renal anaemia drug daprodustat – although that also came with disappointment.
Founder: Tim Barry Year of Establishment: 2013 Headquarters: Chicago, Illinois. Founders: Ali Diab and Rajaie Batniji Year of establishment: 2013 Headquarters: San Mateo, California. As a matter of fact, Kyruus now connects around 300,000 medical providers with over 90 million members across the US. Collective Health.
2013 Oct; 48(10): 943–953. Published online 2013 Jul 2. Mayer-Hamblett N, Rosenfeld M, Treggiari MM et al. Standard Care versus Protocol Based Therapy for New Onset Pseudomonas aeruginosa in Cystic Fibrosis. Pediatr Pulmonol. doi: 1002/ppul.22693. Challenges in Pediatric Study Design and Analysis, and Some Potential Solutions.
Two Highly Cited Researchers, close in name but not location, collaborated on a 2013 Highly Cited Paper about China’s water policies and their socioeconomic, environmental and ecological impacts. Their 2013 paper has been cited 220 times. Integration of green and gray infrastructure for water management. However, unlike chemical (e.g.
Key developments: mRNA vaccines and therapeutics Katalin Karikó In 1989, Katalin Karikó was appointed Assistant Professor at the University of Pennsylvania, where she stayed until 2013. Following this tenure, she became Vice President and later Senior Vice President at BioNTech RNA Pharmaceuticals.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content